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Treatment of the chemically transformed fibroblasts BP-A31 and other cell lines with low concentrations 
of cycloheximide (CHM) for 72 h followed by the removal of the protein synthesis inhibitor leads to the 
proliferation of a-difluoromethylornithine (DFMO)-resistant phenotypes. These drug-resistant cells contain 
almost no ornithine decarboxylase (ODC) activity and concomitantly very low levels of putrescine and sper- 
midine. Southern blot analysis and measurements of ODC activity and intracellular polyamine levels 
showed that the described mechanism of inducing resistance to DFMO triggered by CHM does not involve 
ODC gene amplification, altered transport of the drug or reduced affinity of the enzyme for DFMO. 
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1. INTRODUCTION 
Polyamines have been widely described as play- 
ing an important role in cell proliferation and dif- 
ferentiation [ 1,2]. The ornithine analogue DFMO 
is an irreversible inhibitor of ODC, the key enzyme 
in the polyamine biosynthetic pathway. This drug 
has been extensively used to study the effect of 
ODC inhibition and reduction of intracellular 
levels of polyamines on cell proliferation [3]. 
Chemically transformed mouse fibroblasts such as 
BP-A31 and other cell lines become arrested when 
Dedicated to Dr Luis F. Leloir on the occasion of his 
80th birthday 
Abbreviations: CHM, cycloheximide; DFMO, LY- 
difluoromethylornithine; ODC, ornithine decarbox- 
ylase; DHFR, dihydrofolate reductase; MTX, 
methotrexate 
intracellular polyamine levels are markedly re- 
duced after several days of DFMO addition to the 
tissue culture medium. These cells do not resume 
growth upon drug removal and can be rescued to 
proliferate by the addition of exogenous 
polyamines [4]. 
Several authors have shown that upon long-term 
treatment of various cell types with increasing con- 
centrations of DFMO, drug-resistant cells are ob- 
tained. The most common mechanism involved is 
that of ODC gene amplification, with the conse- 
quent overproduction of ODC enzyme [S-7]. This 
mechanism has also been described for several 
other drugs affecting a variety of different en- 
zymes [8]. Gene amplification of DHFR has been 
shown to occur in MTX-resistant cells following a 
multistep procedure of increasing drug concentra- 
tion, whereas one-step selection with relatively 
high concentration gives rise to resistant cells 
showing mutations in either the enzyme (low drug 
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affinity) or MTX transport mechanism [9,10]. 
Mariani and Shimke have demonstrated that 
amplification of the DHFR gene can also occur in 
a single cell cycle if synchronized cells are treated 
with HO-urea (a reversible inhibitor of DNA 
replication) for 6 h immediately after the begin- 
ning of the S phase [l 11. 
This paper describes that treatment of cultures 
of various cell lines with low concentrations of 
CHM provokes the proliferation of DFMO- 
resistant cells upon removal of the protein syn- 
thesis inhibitor. ODC enzymatic activity, in- 
tracellular polyamine pools and ODC gene pattern 
of the drug-resistant cells have also been studied. 
2. MATERIALS AND METHODS 
2.1. Chemicals and ceil lines 
DFMO was a generous gift from Merrell Dow 
Pharmaceuticals. CHM was purchased from 
Sigma. 
Fibroblasts 3T3-A31, benzo[a]pyrene-trans- 
formed 3T3 fibroblasts BP-3T3 C17-5 (BP-A31), 
the human T lymphoid cells YHHH and the 
human mammary tumor cells MCF-7 were ob- 
tained from frozen stocks in this laboratory. The 
restriction enzyme EcoRI was from Bio-Labs and 
the nitrocellulose paper from Schleicher and 
Schuell BA-85. 
2.2. DFMO-resistant cell culture (BP-CDS) 
BP-A31 cells were plated at 3.7 x 10’ per cm2 in 
35 mm culture petri dishes and grown as in [4]. 
After 24 h they were shifted to fresh medium con- 
taining 0.2/1g/ml of CHM and incubated for 3 
days. Cells were then washed twice with PBS and 
shifted to fresh medium with 5 mM DFMO which 
was replaced every 3 days. 
2.3. Assay of ODC activity 
Cells were washed quickly with cold PBS, im- 
mediately scraped off with a rubber policeman, 
resuspended in 1 ml of 5 mM Tris-HCl buffer, pH 
7.5, containing 2 mM DTT (buffer A) and lysed by 
freeze-thawing several times after 12 strokes in a 
Dounce homogenizer. Cell extracts were centri- 
fuged at 100000 x g for 1 h and the supernatant li- 
quids were dialysed against buffer A and then used 
for ODC activity determinations essentially as 
described by Insel and Fenno [ 121. Protein concen- 
trations were measured by the method of Lowry et 
al. 1131. 
2.4. Determination of intracellular polyamine 
concentrations 
Cell extracts prepared as described above were 
treated with 0.2 M perchloric acid and the super- 
natant fluids obtained after centrifugation for 
15 min at 10000 x g were used for the measure- 
ment of polyamines by dansylation as in [4]. 
2.5. Analysis of genomic DNA 
High-M, DNA was prepared from BP-A31 and 
BP-CD5 cells. For the Southern experiments 10 pg 
DNA was digested with a 5-fold excess of EcoRI. 
The resulting fragments were fractionated by 0.8% 
agarose gel electrophoresis, transferred onto 
nitrocellulose and hybridized as described [14] to 
the nick-translated mouse ODC-cDNA clone 
pODC54, kindly provided by Dr O.A. Jgnne [15]. 
Filters were subjected to autoradiography for 
48-72 h. 
3. RESULTS AND DISCUSSION 
Working with the transformed cell line BP-A3 1, 
we have found that when CHM is added to the 
culture medium at a concentration able to extend 
the entire cell cycle more than 3 times, cells resis- 
tant to high concentrations of DFMO (5-10 mM) 
can be obtained immediately after CHM removal 
(fig.1). The growth in the presence of the drug is 
observed over the entire cell population with no 
cellular death. In contrast, the omission of the 
CHM treatment previous to DFMO addition 
causes growth inhibition and cellular death after 
B-10 days of exposure to the drug at concentra- 
tions as low as 0.5 mM. The DFMO-resistant cells 
(BP-CDS) once selected after the CHM treatment 
can grow continuously for many months in the 
presence of 5-20 mM DFMO with a viability as 
high as that of the parental cells. The growth rate 
of BP-CD5 cells regardless of the presence of 
DFMO is lower than that of the wild-type BP-A31 
cells (fig. 1B). 
Table 1 shows a comparative study of the in- 
tracellular levels of ODC activity and polyamines 
in the wild-type and DFMO-resistant cells. BP- 
CD5 cells contain about lOO-times less ODC activi- 
ty than BP-A31 cells. This extremely low level of 
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Fig.1. (A) Production of the DFMO-resistant cells BP- 
CD5. BP-A31 cells were plated as described in section 2. 
After 24 h they were shifted to the following media: (0) 
control medium, (m) control medium +_ 5 mM DFMO, 
(0) control medium + 0.2pg/ml CHM, (A) control 
medium + 0.2,4ml CHM for 3 days, washed twice 
with PBS and shifted to 5 mM DFMO at the time 
indicated by the thick arrow. The thin arrow shows the 
day when the DFMO-resistant cells were trypsinized and 
replated as the resistant BP-CD5 cells. (B) Growth 
curves of BP-A31 and BP-CD5 cells. (0) Wild-type BP- 
A31, (A) BP-CD5 growing with 5 mM DFMO, (m) BP- 
CD5 growing in the absence of DFMO. 
ODC is reflected in the decreased concentrations 
of polyamines, particularly those of putrescine and 
spermidine with minor changes in the spermine 
content, an observation also described by others 
[ 161. Similar results on the levels of enzyme activity 
and polyamines were obtained when DFMO was 
removed 2 days before the preparation of the crude 
extracts (not shown). In addition, we could not 
Table 1 
detect cadaverine in the wild-type or DFMO- 
resistant cells. 
Since the drug-resistant cells still have a rather 
high content of spermine, it is important to em- 
phasize that BP-A31 cells treated with DFMO 
alone stopped their growth after several days in 
spite of the fact that spermine levels only decreased 
to about one-half of that in the untreated cells [4]. 
Similar observations were reported for several 
other cell lines [ 17-191. The drug-arrested cells can 
only be rescued to grow by supplementation of 
culture medium with putrescine [4]. The results 
shown in table 1 rule out the possibility that BP- 
CD5 cells have an altered DFMO transport or a 
DFMO-insensitive ODC enzyme as has been 
described with other cell lines rendered resistant o 
DFMO [7,20]. 
Since ODC gene amplification is a rather com- 
mon result of drug resistance, we performed a 
Southern blot analysis of the DNAs derived from 
the parental and variant cells using a mouse ODC 
cDNA clone as a probe [15]. Fig.2 shows that the 
normal pattern of the multigene ODC family 
[6,21,22] is equally distributed in the wild-type and 
mutant BP-CD5 cells without any relative increase 
in the intensity of the different bands corre- 
sponding to the resistant cells. This observation is 
a clear indication that no ODC gene amplification 
has occurred. Moreover, we have not detected dif- 
ferences in the ODC-mRNA levels between mutant 
and wild-type cells (not shown). 
The present results are not exclusive to the 
mouse fibroblast cell line BP-A31. DFMO- 
resistant cells can also be obtained using the same 
CHM/DFMO treatment with the normal 
Ornithine decarboxylase activity and intracellular polyamine pools 
of BP-A31 and BP-CD5 cells 
Cells ODC activity Polyamines (nmol/mg protein) 
(nmol/h per 
mg protein) Putrescine Spermidine Spermine 
BP-A3 1 3.62 6.54 16.88 5.58 
BP-CD5 0.04 0.38 0.86 3.09 
ODC activity values given in nmol 14C02 released from L- 
[ l-‘4C]ornithine were corrected for radioactivity in control 
experiments carried out without enzyme 
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Fig.2. Analysis of genomic DNA obtained from wild- 
type BP-A31 (a) and DPMO-resistant BP-CD5 cells (b). 
Each lane contains 10/g EcoRIdigested DNA. Other 
details as in section 2. 
fibroblast 3T3-A31 as well as with the human T 
lymphoid cell line YHHH [14] and the human 
mammary tumor cell line MCF-7 (not shown). 
The above-mentioned observations seem to in- 
dicate that putrescine and spermidine are no longer 
essential for cellular growth if cells have been 
previously treated with low doses of the protein 
synthesis inhibitor CHM. It is known that this 
drug can produce several genetic and epigenetic 
modifications like double replication of 
chromosomal DNA segments [23], superinduction 
of proteins [24,25], superinduction of c-myc 
mRNA [26,27] and a transient reversion of the 
tumoral phenotype in viral and chemically 
transformed cells [28]. The mechanism by which 
DFMO-resistant cells were produced in our case 
does not involve gene amplification, the ap- 
pearance of a DFMO-insensitive ODC, nor a 
decreased transport of DFMO. It seems that CHM 
does not cause damage (at least permanent) to the 
ODC gene or its product, since 6-8 days after 
DFMO removal, the cells show increasing ODC ac- 
tivity with the consequent rise in the levels of 
polyamines. These results suggest hat CHM prob- 
ably acts by inducing the expression of some 
other gene(s), which allows the cell to proliferate 
with very low levels of putrescine and spermidine. 
To our knowledge, this is a novel mechanism of 
resistance to DFMO induced by CHM. Other in- 
hibitors of protein synthesis like histidinol and 
puromycin also used at suboptimal concentrations 
did not produce the effect obtained with CHM 
(not shown). 
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